No connection

Search Results

HRTX vs TKNO

HRTX
Heron Therapeutics, Inc.
BEARISH
Price
$0.85
Market Cap
$160.8M
Sector
Healthcare
AI Confidence
85%
TKNO
Alpha Teknova, Inc.
BEARISH
Price
$2.91
Market Cap
$155.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
HRTX
--
TKNO
--
Forward P/E
HRTX
1.67
TKNO
-7.46
P/B Ratio
HRTX
12.01
TKNO
2.27
P/S Ratio
HRTX
1.04
TKNO
3.85
EV/EBITDA
HRTX
-1142.32
TKNO
-16.07

Profitability

Gross Margin
HRTX
72.64%
TKNO
33.17%
Operating Margin
HRTX
0.09%
TKNO
-41.16%
Profit Margin
HRTX
-13.04%
TKNO
-42.59%
ROE
HRTX
--
TKNO
-22.83%
ROA
HRTX
-0.65%
TKNO
-9.26%

Growth

Revenue Growth
HRTX
-0.5%
TKNO
7.8%
Earnings Growth
HRTX
--
TKNO
--

Financial Health

Debt/Equity
HRTX
9.81
TKNO
0.41
Current Ratio
HRTX
2.48
TKNO
4.58
Quick Ratio
HRTX
1.42
TKNO
3.44

Dividends

Dividend Yield
HRTX
--
TKNO
--
Payout Ratio
HRTX
0.0%
TKNO
0.0%

AI Verdict

HRTX BEARISH

HRTX presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of positive technical momentum (0/100). While the company maintains strong gross margins (72.64%) and a healthy current ratio (2.48), these are overshadowed by an extreme Debt/Equity ratio of 9.81 and a catastrophic 5-year price decline of 94.8%. There is a severe disconnect between the 'Strong Buy' analyst consensus with a $4.33 target and the actual market performance and fundamental leverage.

Strengths
Strong Gross Margin of 72.64%
Healthy liquidity with a Current Ratio of 2.48
Operating margin is near break-even (0.09%)
Risks
Extreme leverage with Debt/Equity at 9.81
Severe long-term value destruction (5Y Change: -94.8%)
Stagnant revenue growth (-0.50% YoY)
TKNO BEARISH

TKNO exhibits severe financial weakness with a Piotroski F-Score of 1/9, indicating critical operational deterioration. While the company maintains a strong liquidity buffer with a current ratio of 4.58 and low debt-to-equity (0.41), it is plagued by deep negative profit margins (-42.59%) and a completely bearish technical trend (0/100). There is a significant disconnect between the optimistic analyst target of $9.00 and the market's reality, evidenced by a 49.6% price decline over the last year. The lack of profitability and poor deterministic health scores make this a high-risk speculative play.

Strengths
Strong short-term liquidity (Current Ratio: 4.58)
Low leverage (Debt/Equity: 0.41)
Positive YoY EPS growth (+18.2%) despite remaining negative
Risks
Critical operational health (Piotroski F-Score: 1/9)
Severe negative profitability (Profit Margin: -42.59%)
Strong bearish technical momentum (Technical Trend: 0/100)

Compare Another Pair

HRTX vs TKNO: Head-to-Head Comparison

This page compares Heron Therapeutics, Inc. (HRTX) and Alpha Teknova, Inc. (TKNO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile